April was the second contraction in 6 months. May's outcome depends on three deals in negotiation.

April closed at -1.01% MoM with 97.37% NRR. The only other negative month in the prior 18 was October 2025 at -0.81%. May isn't done — it'll be decided by what closes from the 3 negotiation deals ($193K ARR / ~$16.1K/mo MRR potential) and the 3 hot deals ($626K ARR / ~$52.2K/mo MRR potential) sitting in Pipedrive. The April damage came from a concentrated cluster of losses (Eden Health, Genius Tag, Vintage Broncos) without enough net new to absorb it. Product works in aesthetics — but the leading indicators say we're not set up to scale on autopilot.

This week's single most important move — per person.

One action each. Click "Open details →" on any card to jump to the relevant discussion section below. Set status as the week progresses; it saves to your browser.

Sales & Growth

CX, Onboarding & Account Growth (TAMs)

Engineering & Product

Customer Success Contractors (Mappa)

Missing someone? The current list reflects what's on the May goals sheet + Pipedrive deal owners + recent payroll/contractor records. Add new cards by editing the source.

Where we stand against this month's goals — with April context.

Click any status dropdown to update live during the meeting. Changes are saved in your browser so they persist on reload.

What the MRR sheet shows that the headline misses.

The -1% MoM number is only the surface. Five things in the customer data make the picture more urgent — and a couple make it more solvable.

A. YoY growth is decelerating fast.

ARR YoY growth has fallen from +96% in January to +85% in Feb to +70% in April. The Q1 new-logo wave (4Ever Young, Confident MedSpa, Genesis Lifestyle, Allure Medical, Sand Cloud, Wedgewood, Inspire expansion) tapered to a trickle in April (Greenwich, Ezer, Kerix, JECT). The April dip isn't just churn — it's the Q1 new-logo wave running out with no clearly-staged second wave behind it.

B. Customer concentration is meaningful.

Pfizer is 22.6% of all MRR. AMP is another 6.7%. The top 10 customers are roughly 53% of the book. That means an October Pfizer outcome (SOC2 unblock or not) effectively decides the year. It also means a single ~$10K churn in the long tail moves the MoM number visibly — exactly what April was.

C. TAM book sizes are wildly unbalanced.

Arthur is sitting on $86.7K of MRR (Pfizer + LiftFund + others). Jason has $63.8K, Blake $56.8K, the CS Team carries $105.3K. Ellie (the high performer) has only $17.7K to work with, and Brian has $10.1K. The TAMs who are crushing have small books; the ones with the big books aren't fully ramped or are senior leaders meant to be doing other things. Arthur's book is trending below 100% in May — early signal that running it personally on top of everything else isn't sustainable.

D. Aesthetics is the wedge — and the concentration.

Med Spa accounts represent roughly 60% of MRR. That's also where the product is most loved. The strategic question: at what point do we explicitly say "we are the data platform for aesthetics" and double down — vs. continuing to seed Healthcare, Retail, Finance opportunistically? The data says the wedge works.

E. Healthcare NRR is flat at 100%.

Healthcare cohort NRR: Jan 105.1% → Feb 100.5% → Mar 99.1% → Apr 100.0%. Anchor accounts (Pfizer, LiftFund, Geode, Turnwell, Athletico, OhMD) are holding but not expanding. There is no MCP/CorralActivate expansion motion in Healthcare today. If we want NRR to print 103%+, this is the segment where the next dollar comes from.

Marketing — 16/30 warm deals (53%).

Sales — Hot deals at 3/10 (30%). Live pipe pulled below.

Hannah & McKenna ramp — McKenna is the blank.

Onboarding — 1/6 transitions (50% of expected pace).

CX response & solve times — both red.

TAMs & NRR — all four at 100% vs 103% target.

QA bug ticket rate — 26% vs <15%.

Stack rank — agree, disagree, or reorder. Status of each is unknown until we walk it.

From Alex. Rank order matters: if anything below has to be cut for the month, it gets cut from the bottom.

The fixable side of a bad April.

We are not in a strategic crisis — we are in an execution gap. The list below is the reason confidence is appropriate.

• $819K of ARR in active sales motion — 3 Hot + 3 Negotiating per Pipedrive. Even at conservative close rates that's ~$25K/mo of net new MRR.
• Ellie at 104.13% NRR, Jason at 100.55% — the TAM-as-profit-center model works when someone fully owns it.
• Onboarding crushed April at 138% of goal (11 vs 8 transitions). Vera's machine works.
• Data freshness held at 100% — every customer wakes up to yesterday's data on time. The other engineering items on the May sheet (CorralActivate Live, Widget React cutover, Table v2, Redshift migration, Airbyte resiliency, SOC2) are not actually shipped — sheet says Live, reality says no. That's a major discussion item, not a win.
• Aesthetics is the wedge — product is well-loved (4Ever Young, AMP, AlluraMD, Annie, Confident MedSpa, Inspire, Genesis, MD Wellness). The wedge is real and expandable.
• Pfizer is a $78K/mo anchor sitting on the platform. SOC2 clear + retention = a meaningful 2026 outcome from this one account alone.
• Data freshness 100% — Lukasz's machine is humming. The most boring KPI on this sheet is also the most important.

What each person leaves this meeting committed to.

Fill these in as we discuss. Saves automatically.